Maze is working on developing treatments for renal, cardiovascular, and metabolic diseases. Its pipeline features two leading experimental candidates for chronic kidney disease: MZE829, currently in a mid-stage study, and MZE782, in an early-stage study with initial data anticipated in the second half of 2025. Read more: https://pharma.economictimes.indiatimes.com/news/pharma-industry/biotech-firm-maze-therapeutics-raises-140-million-in-us-ipo/117763819